NCT04798781View on ClinicalTrials.gov

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2026

Conditions
Gastric CancerHepatocellular Carcinoma
Interventions
DRUG

Telatinib

900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent

DRUG

Keytruda

200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent

Trial Locations (3)

90025

CS Cancer at The Angeles Clinic and Research Institute, Los Angeles

90048

CS Cancer at the Samuel Oschin Cancer Center, Los Angeles

90211

CS Cancer Beverly Hills, Beverly Hills

Sponsors

Collaborators (1)

EOC Pharma
All Listed Sponsors
collaborator

EOC Pharma

INDUSTRY

lead

Andrew Hendifar, MD

OTHER